Cost Per Response/Remission in Biologics Available in Italy for the Treatment of TNF-α Inhibitors-Naïve Patients With Ulcerative Colitis

Global and Regional Health Technology Assessment - Italy
doi 10.1177/2284240318822434
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Aboutscience Srl

Related search

Letter: Effectiveness of Golimumab to Induce Remission in Outpatient Ulcerative Colitis in Italy

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2016English

Psy100 - Cost-Effectiveness Analysis of Second Line Treatment for Patients With Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Maintaining Remission in Distal Ulcerative Colitis and Ulcerative Proctitis

Canadian Journal of Gastroenterology
1990English

Cost-Utility Analysis of Secukinumab Use Versus TNF-Α Inhibitors, in Patients With Ankylosing Spondilytis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Maintaining Remission From Ulcerative Colitis

Prescriber
Pharmacology
2015English

Tacrolimus Therapy as an Alternative to Thiopurines for Maintaining Remission in Patients With Refractory Ulcerative Colitis

Journal of Clinical Gastroenterology
Gastroenterology
2011English

Differential Expression of MUC12, MUC16, and MUC20 in Patients With Active and Remission Ulcerative Colitis

Mediators of Inflammation
ImmunologyCell Biology
2015English

Treatment for Ulcerative Colitis

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
2010English

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

Gastroenterology
HepatologyGastroenterology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy